Physician profile
Rahul Patel
NPI 1063088573
$1,629.03
in general payments reported to CMS, 2019-2025
17 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $242 · 2023: $308 · 2024: $744 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123 · Education: $90.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.89 |
| Education | $90.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $354.72 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $272.41 | 2021-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.57 | 2021-2025 | Lifevest |
| Edwards Lifesciences Corporation | $149.98 | 2024 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $111.62 | 2024 | |
| Medtronic, INC. | $101.54 | 2024 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.46 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $82.97 | 2023-2024 | Wegovy |
| Amgen INC. | $57.94 | 2023 | Repatha, Lumakras |
| Merck Sharp & Dohme LLC | $34.29 | 2024-2025 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $32.77 | 2024-2025 | Evkeeza, Praluent |
| Imperative Care, INC | $28.46 | 2024 | Zoom 88-T Large Distal Platform |
| Daiichi Sankyo INC. | $23.70 | 2023 | Injectafer |
| Atricure, INC. | $21.32 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.89 | 2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.35 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.